ClinicalTrials.gg
CompletedNCT03903705Updated Apr 6, 2025

: A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors

A Phase 1/2 interventional study of Fruquintinib in Combination with Sintilimab in Advanced Solid Tumor, sponsored by Hutchmed. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-04-06.

Sponsored by Hutchmed · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
348
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a phase Ib/II study to evaluate the safety, tolerability, PK profile and preliminary efficacy of fruquintinib monotherapy or plus sintilimab for advanced solid tumors. This study includes fruquintinib plus sintilimab treatment arm (dose escalation phase and dose expansion phase), and fruquintinib monotherapy arm.

Read the detailed description

This study is composed of Fruquintinib plus sintilimab treatment arm and Fruquintinib monotherapy arm.

Fruquintinib plus sintilimab treatment arm:

  • Dose escalation phase: it is planned to enroll about 26-39 patients
  • Dose expansion phase: it is planned to enroll about 309-329 patients, including about 140 patients with endometrial cancer

Fruquintinib monotherapy arm: about 13 patients with advanced endometrial cancer

02

Conditions studied

  • Advanced Solid Tumor

Keywords

  • Fruquintinib
  • Sintilimab
  • VEGFR
  • PD-1
  • Solid Tumor
03

In context

Lead sponsor

Hutchmed is the lead sponsor of 51 studies on the registry; 12 are open to participants now.

Of its 16 completed or terminated interventional studies of FDA-regulated products, 9 (56%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have fully understood and voluntarily sign the ICF for this study (the icf must be signed before any trial-specific procedures are performed);
  • Age of 18-75 years (inclusive); ≥18.5 kg/m2;
  • Tumor types:
  • Fruquintinib plus sintilimab treatment arm
  • Dose escalation phase: patients with or cytologically confirmed inoperable or advanced solid tumors (including but not limited to HCC, ovarian cancer, endometrial cancer, thymic cancer, NSCLC, renal cell carcinoma);
  • Dose expansion phase: histologically or cytologically confirmed inoperable metastatic advanced HCC (Barcelona Clinic Liver Cancer [BCLC] stage B or C), advanced renal cell carcinoma with clear cell component, advanced endometrial cancer, advanced gastric adenocarcinoma or gastroesophageal junction adenocarcinoma, advanced colorectal adenocarcinoma, advanced NSCLC, advanced cervical cancer, etc.;
  • Fruquintinib monotherapy treatment arm: histologically or cytologically confirmed metastatic advanced endometrial cancer that cannot be surgically resected or treated with radical radiotherapy;
  • In the expansion phase, patients should agree to provide tissue specimens for detection of expression levels and/or MSI or dMMR status;
  • Requirement for prior systemic antitumor therapy:
  • Fruquintinib plus sintilimab treatment arm:
  • Dose escalation phase: patients who have failed standard treatment (PD or intolerable toxicity after treatment), have no available standard treatment or cannot receive standard treatment (such as economic limitations);
  • Dose expansion phase:
  • Part 1
  • Patients (HCC, renal cell carcinoma, endometrial cancer, gastric adenocarcinoma or gastroesophageal junction adenocarcinoma, colorectal adenocarcinoma, cervical cancer, NSCLC) should have PD or intolerable toxicity after 1 standard treatment, or cannot receive standard treatment (such as economic limitations or patient's wishes, etc.). Among them, requirements of standard treatment are defined as follows:
  • Patients with HCC who have received 1 molecular targeted therapy (sorafenib or lenvatinib) or/and systemic chemotherapy (arsenious acid monotherapy or oxaliplatin-based combination therapy);
  • Patients with renal cell carcinoma who have received 1 standard systemic antitumor therapy (sunitinib, sorafenib, pazopanib, axitinib, cabozantinib, bevacizumab plus IFN-α, temsirolimus);
  • Patients with endometrial cancer who have received ≤2 line of platinum-based double drug systemic antitumor therapy (excluding hormonal therapy) and had PD or Grade ≥3 SAE, or had recurrence or PD after completion of at least 4 cycles of platinum-based double drug chemotherapy. Patients with recurrence or metastasis during or within 12 months after completion of /adjuvant chemotherapy with platinum-based regimen are considered to have received treatment (4 cycles are required for neoadjuvant/adjuvant chemotherapy, and if less than 4 cycles, it is also eligible to have PD or Grade ≥3 SAE during the treatment);
  • Patients with cervical cancers who have recurrent or metastasized squamous cell carcinoma, adenocarcinoma, or adeno-squamous carcinoma after at least one line of platinum-based chemotherapy (patients are considered to have received first-line treatment if they have recurrent or metastasized during or within 6 months after platinum-based neoadjuvant or adjuvant chemotherapy);
  • Patients with gastric adenocarcinoma and gastroesophageal junction adenocarcinoma who have failed prior standard chemotherapy and can provide tumor tissues for PD-L1 expression detection with CPS ≥1;
  • Patients with colorectal adenocarcinoma previously treated with fluoropyrimidine+leucovorin calcium+platinum or irinotecan+cetuximab/bevacizumab.
  • Advanced NSCLC (stage IV NSCLC diagnosed per AJCC 8th version):
  • Patients with negative driver gene (EGFR/ALK/ROS-1 negative) who have failed prior standard treatment or have intolerable toxicity, or cannot receive or are unwilling to receive current standard treatment, and with PD-L1 expression level TPS (tumor proportion score) ≥1% tested by central laboratory arranged by the sponsor.
  • Patients with NSCLC diagnosed with squamous cell carcinoma do not require test of EGFR mutation, ALK and ROS1 fusion per current diagnosis and treatment guidelines. Other non-squamous NSCLC patients can be included if they have a prior test report demonstrating no driver gene mutation/rearrangement (EGFR, ALK, ROS1); if there is no prior corresponding gene report, archived or fresh tissue needs to be collected for testing at the study site, or at the central laboratory arranged by sponsor.
  • Patients who have recurrence or metastasis during or within 6 months after prior neoadjuvant/adjuvant therapy are considered as having received first-line therapy.
  • Part 2
  • To enroll patients with renal cell carcinoma who have not received systemic therapy, the specific requirements are as follows:
  • Patients with renal cell carcinoma have not received any prior systemic antitumor therapy for renal cell carcinoma (patients with recurrence or PD >6 months after postoperative adjuvant chemotherapy can be enrolled), and patients with prior cytokine therapy are allowed.
  • Fruquintinib monotherapy arm: patients with histologically or cytologically confirmed advanced recurrent or metastatic endometrial cancer who cannot be surgically resected or treated with radical radiotherapy and have failed at least 1 standard treatment (including PD and intolerable toxicity).
  • performance status (ECOG PS) of 0 or 1;
  • Class A (\<7 points) for liver function, only applicable to patients with HCC;
  • Measurable tumor lesions per 1.1, where patients with gastric tumor are required to have outside of the stomach (in the dose escalation phase, patients with only the evaluable lesions are acceptable); if the lesion priorly treated with local therapy (radiotherapy, ablation, interventional therapy, etc.) is the only lesion, there must be definite imaging evidence of PD for that lesion;
  • Laboratory test results of bone marrow, liver and kidney function, and coagulation function within 7 days before the first dose should meet the following criteria (no blood transfusion, blood products, granulocyte colony-stimulating factor or other hematopoietic stimulating factor correction within 7 days before the laboratory test)

    • (ANC) ≥1.5×109/L and ≥100×109/L (platelets ≥80×109/L in patients with HCC) and ≥90 g/L;
    • Serum total (TBIL) ≤1.5 times (×ULN);
    • (ALT) and/or aspartate aminotransferase (AST) ≤1.5×ULN without liver metastases; ALT and/or AST ≤3×ULN with liver metastases and HCC;
    • Serum albumin ≥28 g/L;
    • Serum creatinine ≤1.5×ULN or ≥50 mL/min (calculated per Cockcroft-Gault formula);
    • Protein urine \< 2+; if protein urine ≥ 2+, 24-hour protein urine quantification should be \<1 g;
    • (INR) ≤1.5 and activated partial thromboplastin time (APTT) ≤1.5×ULN (except for prophylactic use of anticoagulant drugs);
  • of ≥12 weeks;
  • Female of must have a negative blood pregnancy test within 7 days before the first dose. Male or female patients of childbearing potential should voluntarily use an effective method during the study and within 6 months after the last dose of study drug, such as double-barrier contraceptive method, condom, oral or injectable contraceptives, intrauterine device, abstinence, etc. All female patients are considered to be of childbearing potential unless they are , have undergone artificial menopause, or are sterilized (hysterectomy, excision of both adnexa).

Exclusion criteria

Exclusion Criteria:

  • The AEs related to prior antitumor therapy which do not recover to ≤ Grade 1 before the first dose, except alopecia and peripheral neurotoxicity of CTCAE Grade ≤2 caused by platinum chemotherapy;
  • Patients with other malignant tumors (except cured cutaneous basal cell carcinoma or squamous cell carcinoma, cervical carcinoma in situ) within 5 years before screening, only applicable to patients in expansion phase;
  • Histological diagnosed fibrolamellar HCC, sarcomatoid HCC or mixed components of the above pathological types; or gastric squamous cell carcinoma or gastric adenosquamous carcinoma; or carcinosarcoma or sarcoma (endometrial cancer); or pathological diagnosis MSI-H or dMMR (endometrial cancer)
  • Patients with previous or screening stage central nervous system (CNS) during screen period (for lung cancer patients with who have prior treatment, if there is no evidence of radiographic progression within ≥4 weeks before the first dose of study drug, and are clinically stable for ≥2 weeks after treatment, and have discontinued within 3 days before the first dose, the patient could be enrolled; for patients with untreated, asymptomatic lung cancer with brain metastasis [i.e., no neurological symptoms, no need for corticosteroid or antiepileptic treatment, no brain metastasis >1.5 cm in long diameter, no significant edema around brain metastasis], they could be enrolled);
  • Systemic antitumor therapy approved or under study within 4 weeks before the first dose, including but not limited to: chemotherapy (oral fluoropyrimidines of 2 weeks), endocrine therapy, biological immunotherapy, targeted therapy (small molecule targeted therapy washout period of 2 weeks or 5 half-lives, whichever shorter), Traditional Chinese Medicine treatment (Traditional Chinese Medicine treatment with definite antitumor indications in the instructions, a 1-week washout period before the first dose is acceptable);
  • Radical radiotherapy (including more than 25% bone marrow radiotherapy) within 4 weeks before the first dose;
  • Brachytherapy (such as implantation of radioactive particles) within 60 days before the first dose;
  • Patients previously treated with any anti-programmed cell death receptor 1 () antibody, anti-PD-L1 antibody, anti-PD-L2 antibody or anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) antibody (or any other antibody acting on T cell costimulation or checkpoint pathway) (only for the fruquintinib plus sintilimab treatment arm), or fruquintinib;
  • Corticosteroids (dose >10 mg/day prednisone or equivalent of other corticosteroids) or other drugs for systemic treatment within 4 weeks before the first dose; nasal spray, inhalation or other topical use of corticosteroids (i.e., no more than 10 mg/day prednisone or equivalent of other glucocorticoids) are allowed;
  • Patients with any active disease requiring systemic treatment (i.e., use of disease remission drugs, glucocorticoids or immunosuppressive drugs) within the past 2 years; patients who only need replacement therapy (thyroid, adrenal or pituitary dysfunction with thyroid, insulin or physiological glucocorticoid replacement therapy) can be enrolled;
  • Any live or attenuated within 4 weeks before the first dose or planned administration during the study;
  • Major surgical operation within 60 days before the first dose;
  • Any surgery or invasive treatment within 4 weeks before the first dose (stable fistula formation required for fistulization for 4 weeks, except needle , venous fistula); or unhealed wounds, ulcers, fractures;
  • Uncontrolled malignant pleural effusion, ascites or pericardial effusion (defined as not effectively controlled by diuretics or paracentesis, as judged by the investigator);
  • Patients with hypertension uncontrolled by drugs, defined as: systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg;
  • Patients with any disease or condition that affects drug absorption, or the patient could not take the drug orally;
  • Strong cytochrome P450 (CYP) 3A4 inducer/inhibitor, p-glycoprotein (P-gp) substrate and breast cancer resistance protein (BCRP) substrate within 2 weeks or less than 5 half-lives (whichever is longer) before the first dose;
  • Patients with active gastric and duodenal ulcer, ulcerative colitis and other gastrointestinal diseases or unresected tumor with active bleeding, or other conditions that may cause gastrointestinal bleeding and perforation as judged by the investigator; or patients with prior gastrointestinal perforation or gastrointestinal fistula who had not recovered after surgical treatment;
  • Patients with evidence or history of bleeding tendency (such as melena, hematemesis, hemoptysis, bloody feces, etc.) within 2 months before the first dose, regardless of severity;
  • Tumor invading major vascular structures, such as pulmonary artery, superior/inferior vena cava, etc. found during screening, with greater risk of bleeding judged by the investigator;
  • Patients with a history of arterial thrombosis or deep venous thrombosis within 6 months before the first dose; or patients with stroke events and/or within 12 months; except that patients with thrombosis caused by implantable venous infusion pump or catheter, or patients with stable superficial venous thrombosis after conventional anticoagulant therapy;
  • Patients with cardiovascular disease, including but not limited to acute myocardial infarction, severe/unstable angina or coronary artery bypass grafting within 6 months before the first dose; congestive heart failure of (NYHA) class ≥ 2; (LVEF) of \< 50%;
  • Patients with an active infection or unexplained fever (body temperature >38.5oC) during the screening period or before the first dose;
  • Patients with active pulmonary tuberculosis who are receiving anti-tuberculosis treatment or received anti-tuberculosis treatment within 1 year before the first dose;
  • Patients with prior and current pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonia, severely impaired pulmonary function and other conditions that may interfere with the detection and treatment of suspected drug-related pulmonary toxicity;
  • Known (HIV) infection;
  • Known history of clinically significant liver disease, including active viral hepatitis, ( virus surface antigen [HBsAg] and/or hepatitis B virus core antibody [HbcAb] positive, hepatitis B virus [HBV] DNA >10000 copies/mL or > 2000 IU/mL; virus [HCV] antibody positive and HCV RNA positive), or other active hepatitis, clinically significant moderate to severe cirrhosis;
  • Other clinical drug treatment that has not been approved or marketed in China within 4 weeks before the first dose;
  • Women who are pregnant (positive pregnancy test before dose) or breastfeeding;
  • Known to any component of the sintilimab, fruquintinib formulation, or prior history of severe allergy to any other monoclonal antibody;
  • Patient with any other condition or laboratory abnormalities that, in the opinion of the investigator, will increase the risk of study participation or interfere with the interpretation of study results, and is not suitable for the clinical study.
Terms in these criteria, in plain language(38)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
348 participants (actual)

Study arms

  • Experimental
    VEGFR cohort:

    Fruquintinib

    Drug: Fruquintinib in Combination with Sintilimab

Interventions

  • DrugFruquintinib in Combination with Sintilimab

    Drug pages: HMPL-013 · Sintilimab

    Fruquintinib plus Sintilimab: Cohort A: Fruquintinib 3 mg QD, oral dosing, 3 weeks on/1 weeks off +Sintilimab 200mg Q4W, intravenous dosing. Cohort B: Fruquintinib 4 mg QD, oral dosing, 3 weeks on/1 weeks off +Sintilimab 200mg Q4W, intravenous dosing Cohort C: Fruquintinib 5 mg QD, oral dosing, 2weeks on/1 weeks off + Sintilimab 200mg Q3W, intravenous dosing Cohort E: Fruquintinib 3 mg QD, continuous, oral dosing, + Sintilimab 200mg Q3W, intravenous dosing Fruquintinib monotherapy arm: Fruquintinib 5 mg QD, oral dosing, 3 weeks on/1 weeks off Patients will be treated until disease progression, death, unacceptable toxicity, loss of follow-up, withdrawal of consent or other conditions meet the end of treatment criteria.

    Also known as: Fruquintinib

06

What researchers measure

Primary outcomes

  1. Dose escalation phase: Safety outcome evaluation - DLT, MTD/RP2D

    Dose escalation phase: To evaluate the safety and tolerability of fruquintinib plus sintilimab for advanced solid tumors in the dose escalation phase, to observe dose-limiting toxicity (DLT), the maximum tolerated dose (MTD) and/or to determine the recommended phase 2 dose (RP2D) and administration strategy of the combination therapy.

    Time frame: From first dose to 30 days post the last dose

  2. Dose expansion phase (except EMC cohort): efficacy outcome evaluation - ORR based on the investigator's tumor assessment

    Dose expansion phase (except endometrial cancer \[EMC\] cohort): ORR assessed by investigator

    Time frame: very 6 weeks since Cycle1 Day 1, and every 12 weeks after Week 48, until disease progression or death or new anti-cancer therapy or loss of follow-up or withdrawal of consent

  3. Dose expansion phase (EMC cohort): efficacy outcome evaluation - ORR based on IRC's tumor assessment

    Dose expansion phase (EMC cohort): ORR by IRC

    Time frame: Every 6 weeks since Cycle1 Day 1, and every 12 weeks after Week 48, until disease progression or death or new anti-cancer therapy or loss of follow-up or withdrawal of consent

  4. Fruquintinib monotherapy arm: efficacy outcome evaluation - ORR based on investigator's tumor assessment

    Fruquintinib monotherapy arm: ORR by investigator

    Time frame: Every 6 weeks since Cycle1 Day 1, and every 12 weeks after Week 48, until disease progression or death or new anti-cancer therapy or loss of follow-up or withdrawal of consent

Secondary outcomes

  1. Immunogenicity Assessments for Anti-drug Antibody(ADA)

    Immunogenicity Assessments for Anti-drug Antibody(ADA)

    Time frame: From Cycle 1, 2, 4, 6, 8, 12 (each cycle is 28 days) and the safety visit for Sintilimab until disease progression or death or new anti-cancer therapy or withdrawal of consent

  2. pharmacokinetics (PK) Assessments

    To evaluate the PK profile of fruquintinib plus sintilimab

    Time frame: From Cycle 1 for Fruquintinib; Cycle 1, 2, 3, 4 for Sintilimab in the dose escalation phase, and Cycle 1, 2, 4, 12 for dose expansion phase.

  3. Dose expansion phase (except EMC cohort): Efficacy outcome evaluation - DCR, PFS, OS, DoR, TTR based on the investigator's tumor assessment

    Dose expansion phase (except EMC cohort): DCR, PFS, OS, DoR, TTR by investigator

    Time frame: Every 6 weeks since Cycle1 Day 1, and every 12 weeks after Week 48, until disease progression or death or new anti-cancer therapy or loss of follow-up or withdrawal of consent

  4. Dose expansion phase (EMC cohort): Efficacy outcome evaluation - ORR, DCR, PFS, OS, DoR, TTR based on the investigator's tumor assessment

    Dose expansion phase (EMC cohort): ORR, DCR, PFS, OS, DoR, TTR by investigator

    Time frame: Every 6 weeks since Cycle1 Day 1, and every 12 weeks after Week 48, until disease progression or death or new anti-cancer therapy or loss of follow-up or withdrawal of consent

  5. Dose expansion phase (EMC cohort): Efficacy outcome evaluation - DCR, PFS, OS, DoR, TTR based on the IRC's tumor assessment

    Dose expansion phase (EMC cohort): DCR, PFS, OS, DoR, TTR by IRC

    Time frame: Every 6 weeks since Cycle1 Day 1, and every 12 weeks after Week 48, until disease progression or death or new anti-cancer therapy or loss of follow-up or withdrawal of consent

  6. Safety outcome evaluation

    Overall incidence of AEs, incidence of Grade ≥ 3 AEs, etc.

    Time frame: From first dose to 30 days post the last dose

  7. Biomarker evaluation

    Detect the expression of PD-L1 and/or other biomarkers in tumor tissues of patients, and analyze the relevant efficacy to provide reference for determining the dominant population.

    Time frame: From first dose to 30 days post the last dose

Other outcomes

  1. Exploratory outcome

    Evaluate the potential biomarkers related to the antitumor effect of fruquintinib plus sintilimab.

    Time frame: From first dose to 30 days post the last dose

07

Study locations

1 site
  • Shanghai East Hospital
    Shanghai, Shanghai 201203, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2019 to primary completion in Nov 2023, 54 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2019
First posted
Apr 4, 2019
StartActual
Apr 25, 2019
Primary completionActual
Nov 15, 2023
CompletionActual
Dec 16, 2024
Last update
Apr 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03903705
Lead sponsor
Hutchmed
Responsible party
Sponsor
First posted
Apr 4, 2019
Start date
Apr 25, 2019
Primary completion
Nov 15, 2023
Completion
Dec 16, 2024
Last update
Apr 6, 2025

Study contacts

Jin Li
principal investigator · Shanghai East Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: HMPL-013 · Sintilimab

Start the discussion